Analysis of the efficacy of prophylactic tranexamic acid in preventing postpartum bleeding: systematic review with meta-analysis of randomized clinical trials

Background: Postpartum Hemorrhage (PPH) is one of the main causes of maternal mortality, mainly in the poorest regions of the world, drawing attention to the need for strategies for preventing it. This study aims to evaluate the efficacy of prophylactic administration of Tranexamic Acid (TXA) in decreasing blood loss in pregnant women in delivery, preventing PPH. Methods: Systematic review of randomized clinical trials. We searched for publications in PubMed, EMBASE and Cochrane Library databases, with the uniterms "postpartum, puerperal hemorrhage" and "tranexamic acid", published between January of 2004 and January of 2020. The eligibility criteria were trials published in English with pregnant women assessed during and after vaginal or cesarean delivery about the effect of prophylactic use of TXA on bleeding volume. The random-effects model was applied with the DerSimonian-Laird test and the Mean Difference (MD) was calculated for continuous variables together with each 95% CI. This system-atic review was previously registered in the PROSPERO platform under the registration n & DEG; CRD42020187393. Results: Of the 630 results, 16 trials were selected, including one with two different doses, per-forming a total of 6731 patients. The intervention group received a TXA dose that varied between 10 mg.kg ⠁1 and 1g (no weight calculation). The TXA use was considered a protective factor for bleeding (MD:-131.07; 95% CI:-170.00 to-92.78; p = 0.000) and hemoglobin variation (MD:-0.417; 95% CI:-0.633 to-0.202; p = 0.000). In the subgroup analysis related to the cesarean pathway, the effect of TXA was even greater.Conclusion: The prophylactic use of tranexamic acid is effective in reducing the post-partum bleeding volume. PROSPERO registration ID: CRD42020187393. & COPY; 2022 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).